CA-CROWN-BIOSCIENCE
21.8.2024 14:31:31 CEST | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting services. This collaboration unites decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space.
Customers will benefit from combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase clinical trials more rapidly and effectively. This alliance aims to determine the optimal and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of superior oncology therapeutics to patients.
From today, customers can access consulting services to ensure an integrated drug development approach, including:
- Strategic preclinical development planning
- Study data analysis, interpretation and advice
- Regulatory guidance
- De novo assay development
- Grant review
Alex Slater, Senior Vice President of Commercial, commented: ‘’Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO. This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.’’
Ryan Gifford, Vice President of Global Laboratory Services, Business Development, shares: ‘’We are delighted to collaborate with Crown Bioscience and view this as a valuable synergy. Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.’’
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
About CTI Clinical Trial & Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, research service organization, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides clinical and disease area expertise with nuanced regulator support. CTI also offers a fully integrated multi-specialty clinical research site and complete global laboratory services. Now in its third decade, CTI is one of the 20 largest contract research organizations in the world, with associates in more than 60 countries across six continents. CTI is headquartered in the Greater Cincinnati area, with operations across North America, Europe, Latin America, MEA, and Asia-Pacific. For more information, visit www.ctifacts.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821624556/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 13:00:00 CEST | Press release
The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 11:00:00 CEST | Press release
Expansion builds on North American program success and brings flexible invoicing and net terms to Aventon’s growing retailer network in Europe TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 10:49:00 CEST | Press release
Alpaca has completed its acquisition of European fintech WealthKernel, which will now operate as Alpaca Europe The acquisition gives Alpaca a regulated brokerage and custody presence across the UK and EU Alpaca is also launching European equities trading, beginning with Germany’s Xetra exchange, with Euronext markets and the London Stock Exchange expected to follow Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulato
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 09:52:00 CEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom